Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 ug/mL using SARS-CoV-2 Inhibitor Screening Kit .Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
Lyophilized from 0.22 im filtered solution in PBS, pH 7.4 . Normally trehalose is added as protectant before lyophilization.
Formulierung:
Lyophilized
Target-Kategorie:
S
Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.472 ug/mL (QC tested).
Immobilized SARS-CoV-2 S1 protein, His Tag at 2 ug/mL (100 uL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 with a linear range of 0.2-1.95 ng/mL (QC tested).
Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 ug/mL (Routinely tested).
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody was incubated with SARS-CoV-2 pseudotyped virus at 37C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.
FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S protein RBD used is 5 ug/ml. The IC50 is 10.33 ug/ml (Routinely tested).
FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S1 protein used is 3 ug/ml. The IC50 is 1.352 ug/ml (Routinely tested).
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
